Alnylam Pharmaceuticals (ALNY) Soars 2.25% on Positive Drug Opinion

Alnylam Pharmaceuticals (ALNY) shares rose 0.31% today, reaching their highest level since March 2025 with an intraday gain of 2.25%.

The strategy of buying ALNY shares after they reached a recent high and holding for 1 week yielded moderate returns over the past 5 years, with a 7.5% annualized gain. However, the Sharpe ratio was low at 0.4, indicating modest risk-adjusted returns. The strategy showed a peak drawdown of 35.4% during the 2023 bear market, reflecting its vulnerability in market downturns. Overall, while the strategy provided some growth, it was not immune to market volatility, highlighting the importance of considering risk factors in such a volatile sector as biotechnology.

Alnylam Pharmaceuticals' stock price has been influenced by several recent developments. On April 28, 2025, the company received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for Vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy. This regulatory progress is expected to have a positive impact on the stock, as it brings the drug one step closer to market approval in the European Union.

Analysts have also shown favorable sentiment towards Alnylam. Citi analyst David Lebowitz reiterated a Buy rating with a price target of $364.00. TD Cowen analyst Ritu Baral maintained a Buy rating with a price target of $371.00. Additionally, Chardan Capital increased their target price from $300.00 to $325.00 and gave a "buy" rating. These positive ratings and target price updates reflect analysts' confidence in the company's growth prospects and the potential of its pipeline.